SECTOR : Biotech
ENTRY DATE : 2010
EXIT DATE : 2016
BUSINESS : Venture Capital
WEB : www.xention.com

Xention

Discovery and development of new drugs modulating ion channels

Xention is a biopharmaceutical company specialised in research and development activities concerning ion channel-modulating drugs, which represent key targets especially for cardiovascular indications. Xention is currently developing two programmes intended to treat atrial fibrillation (the most common form of cardiac arrhythmia), one focused on the Kv1.5 target, currently in clinical phase II trials and to which Servier has purchased an exclusive option (outside the United States and Japan), and the other focused on the IKAch target, currently at the pre-clinical stage. In addition, the company has entered into various partnerships with pharmaceutical laboratories covering use of its ion channel R&D platform.

PRESS RELEASE(S) :

20/07/2005• XENTION RAISES £11 MILLION IN PRIVATE EQUITY PLACEMENT
Lire